Splenic granulopoiesis and S100A9 drive resistance to checkpoint inhibitors conferred by liver metastases
Authors list
Rebecca J Lee Steven Hooper Laura J Pallett Mariana Diniz Tate McKinnon-Snell Zoe Ramsden Nick Rabas Stefan Boeing Oliver Kennedy Charlotte Buttercase Gloryanne Aidoo-Micah Gareth Price Sarah C Macfarlane Sasha Bailey Jessica Davies Anandita Mathur Ginervra Pistocchi Alexandrine Carminati Avinash Gupta Patricio Serra Brian Davidson Joerg-Matthias Pollok Venizelos Papayannopoulos Ilaria Malanchi Paul Lorigan Mala K Maini Erik Sahai
Toggle all authors (27)
This article is a preprint. Preprints have not been peer-reviewed.
You can read more about preprints.
Abstract
Here, we investigate why liver metastases reduce the efficacy of immune checkpoint inhibitors (CPI). The poor prognosis of patients with liver metastases is associated with a systemic increase in neutrophils. Using experimental models, we confirm that mice with liver metastases respond poorly to CPI, have elevated neutrophils and suppress the response of subcutaneous lesions to CPI. We demonstrate that liver metastases, acting partly via IL-6, boost granulopoiesis in the spleen and promote the generation of immature S100A9hi neutrophils that suppress T-cell proliferation. Human liver metastases exhibit a similar increase in S100A9hi neutrophils. Neutrophil depletion attenuates the growth of liver metastases, but not subcutaneous metastases. Moreover, genetic deletion of S100A9 enables liver metastases to be effectively treated with CPI, and prevents liver metastases from suppressing the response in subcutaneous metastases. Thus, we document how liver metastases specifically change splenic granulopoiesis leading to changes in the microenvironment of non-hepatic lesions, and how targeting a key neutrophil protein restores the efficacy of CPI.
Details
Archive
bioRxiv
Available online
Publication date
Keywords
Type of publication
